AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30722059 — intervention group
Group type: COMPARATOR
Intervention: Moxifloxacin 400 mg IV every 24 hours
Number of subjects: 551
Study 28629896 — intervention group
Group type: COMPARATOR
Intervention: CRT (chemoradiotherapy)
Number of subjects: 60
Study 28629896 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT plus panitumumab
Number of subjects: 60
Study 25887528 — intervention group
Group type: EXPERIMENTAL
Intervention: NL plus earplugs and eye masks (NLEE)
Number of subjects: 40
Study 25887528 — intervention group
Group type: EXPERIMENTAL
Intervention: NL plus melatonin (NLM)
Number of subjects: 40
Study 25887528 — intervention group
Group type: COMPARATOR
Intervention: NL night
Number of subjects: 40
Study 23969143 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative care program including 2 days of intensive training, a stepped care protocol, depression management toolkit, and scheduled meetings with a consultant psychiatrist.
Number of subjects: 227
Study 23969143 — intervention group
Group type: COMPARATOR
Intervention: Usual care by primary care physicians (PCPs).
Number of subjects: 227
Study 21432728 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-efficacy intervention
Number of subjects: 677
Study 21432728 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-affirmation intervention
Number of subjects: 677
Study 21432728 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intervention (self-efficacy and self-affirmation)
Number of subjects: 677
Study 21432728 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 677
Study 19746673 — intervention group
Group type: EXPERIMENTAL
Intervention: Solubilized 5% BPO gel
Number of subjects: 65
Study 19746673 — intervention group
Group type: COMPARATOR
Intervention: 5% BPO/1% clindamycin
Number of subjects: 65
Study 17760245 — intervention group
Group type: COMPARATOR
Intervention: Sucrose
Number of subjects: 102
Study 17760245 — intervention group
Group type: COMPARATOR
Intervention: Breast feeding
Number of subjects: 102
Study 17760245 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 102
Study 15007119 — intervention group
Group type: EXPERIMENTAL
Intervention: Flupirtine (FLU), n = 13
Number of subjects: 28
Study 15007119 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA), n = 15
Number of subjects: 28
Study 11095452 — intervention group
Group type: EXPERIMENTAL
Intervention: sc insulin (INS)
Number of subjects: 9
Study 9347196 — intervention group
Group type: EXPERIMENTAL
Intervention: Wpos (positive work)
Number of subjects: 12
Study 9347196 — intervention group
Group type: EXPERIMENTAL
Intervention: Wneg (negative work)
Number of subjects: 12
Study 8341987 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole and amoxycillin combination therapy (n = 30)
Number of subjects: 60
Study 8341987 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole monotherapy (n = 30)
Number of subjects: 60
Study 3088652 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 0.25 mg at 8 a.m.
Number of subjects: 5
Study 3088652 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 0.25 mg at 11 p.m.
Number of subjects: 5
Study 3088652 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 0.25 mg at 2 a.m.
Number of subjects: 5
Study 3088652 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 0.25 mg at 5 a.m.
Number of subjects: 5
Study 3088652 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 29488152 — intervention group
Group type: EXPERIMENTAL
Intervention: DS-8500a 25 mg
Number of subjects: 100
Study 29488152 — intervention group
Group type: EXPERIMENTAL
Intervention: DS-8500a 50 mg
Number of subjects: 100
Study 29488152 — intervention group
Group type: EXPERIMENTAL
Intervention: DS-8500a 75 mg
Number of subjects: 100
Study 29488152 — intervention group
Group type: COMPARATOR
Intervention: Sitagliptin 50 mg
Number of subjects: 100
Study 29488152 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 26934259 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin degludec/liraglutide (n=278; maximum dose, 50 U of degludec/1.8 mg of liraglutide)
Number of subjects: 557
Study 26934259 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine (n=279; no maximum dose)
Number of subjects: 557
Study 26934259 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin degludec/liraglutide
Number of subjects: 557
Study 24628438 — intervention group
Group type: EXPERIMENTAL
Intervention: Cogmed Working Memory Training (CWMT)
Number of subjects: 51
Study 24628438 — intervention group
Group type: COMPARATOR
Intervention: Placebo (nonadaptive) training
Number of subjects: 51
Study 23509088 — intervention group
Group type: EXPERIMENTAL
Intervention: Low coffee consumption (< 200 ml/day)
Number of subjects: 142
Study 23509088 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate coffee consumption (200‐450 ml/day)
Number of subjects: 142
Study 23509088 — intervention group
Group type: EXPERIMENTAL
Intervention: High coffee consumption (> 450 ml/day)
Number of subjects: 142
Study 23509088 — intervention group
Group type: EXPERIMENTAL
Intervention: Boiled Greek type of coffee
Number of subjects: 142
Study 20077301 — intervention group
Group type: EXPERIMENTAL
Intervention: High nitrate levels in drinking water
Number of subjects: 0
Study 20077301 — intervention group
Group type: COMPARATOR
Intervention: Lowest tertile of nitrate levels in drinking water
Number of subjects: 0
Study 18768350 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 150 mg
Number of subjects: 3834
Study 18768350 — intervention group
Group type: COMPARATOR
Intervention: Losartan 50 mg (antihypertensive dose)
Number of subjects: 3834
Study 16847534 — intervention group
Group type: EXPERIMENTAL
Intervention: High BrAC (Study 1)
Number of subjects: 152
Study 16847534 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol condition (Study 2)
Number of subjects: 152
Study 16847534 — intervention group
Group type: COMPARATOR
Intervention: Placebo condition (Study 2)
Number of subjects: 152
Study 16847534 — intervention group
Group type: COMPARATOR
Intervention: No-alcohol condition (Study 2)
Number of subjects: 152
Study 12756157 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse facilitator (supervised nurse to initiate and titrate beta-blockers)
Number of subjects: 169
Study 12756157 — intervention group
Group type: COMPARATOR
Intervention: Provider and patient notification (computerized provider reminders and patient letters advocating beta-blockers)
Number of subjects: 169
Study 12756157 — intervention group
Group type: COMPARATOR
Intervention: Control (provider education)
Number of subjects: 169
Study 12756157 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse facilitator
Number of subjects: 169
Study 12756157 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 169
Study 12756157 — intervention group
Group type: COMPARATOR
Intervention: Provider and patient notification
Number of subjects: 169
Study 11307807 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral anticoagulants (OA)
Number of subjects: 433
Study 9196608 — intervention group
Group type: EXPERIMENTAL
Intervention: Once daily (OD) subcutaneous injections of GH at a total dose of 6 IU/m2/day
Number of subjects: 19
Study 9196608 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice daily (BID) subcutaneous injections of GH at a total dose of 6 IU/m2/day
Number of subjects: 19
Study 9196608 — intervention group
Group type: COMPARATOR
Intervention: Both OD and BID groups
Number of subjects: 19
Study 8198761 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release formulation (Orfil retard enteric coated tablet)
Number of subjects: 24
Study 8198761 — intervention group
Group type: COMPARATOR
Intervention: Plain tablet (reference drug)
Number of subjects: 24
Study 3798537 — intervention group
Group type: EXPERIMENTAL
Intervention: Russell's viper venoid (0.5 ml subcutaneous injection followed by two booster injections at four-week intervals)
Number of subjects: 12
Study 3798537 — intervention group
Group type: COMPARATOR
Intervention: Control group (6 subjects)
Number of subjects: 12
Study 29729393 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurofeedback
Number of subjects: 0
Study 29729393 — intervention group
Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 0
Study 27756495 — intervention group
Group type: EXPERIMENTAL
Intervention: Master of Taste (MT)
Number of subjects: 112
Study 27756495 — intervention group
Group type: EXPERIMENTAL
Intervention: Master of Taste + NAO (MT + NAO)
Number of subjects: 112
Study 27756495 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 112
Study 24788028 — intervention group
Group type: EXPERIMENTAL
Intervention: Providing case management
Number of subjects: 638
Study 24788028 — intervention group
Group type: EXPERIMENTAL
Intervention: Offering transportation vouchers or free parking
Number of subjects: 638
Study 24788028 — intervention group
Group type: EXPERIMENTAL
Intervention: Offering outreach
Number of subjects: 638
Study 23197780 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) with insulin
Number of subjects: 0
Study 23197780 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin
Number of subjects: 0
Study 23197780 — intervention group
Group type: COMPARATOR
Intervention: PRP alone
Number of subjects: 0
Study 23197780 — intervention group
Group type: COMPARATOR
Intervention: Akt inhibitor (wortmannin)
Number of subjects: 0
Study 23197780 — intervention group
Group type: COMPARATOR
Intervention: FGFR-1 inhibition
Number of subjects: 0
Study 23197780 — intervention group
Group type: COMPARATOR
Intervention: EGFR activity
Number of subjects: 0
Study 23197780 — intervention group
Group type: COMPARATOR
Intervention: ErbB2 inhibition
Number of subjects: 0
Study 19497708 — intervention group
Group type: EXPERIMENTAL
Intervention: Quiet conditions using a cellular phone (QCP)
Number of subjects: 20
Study 19497708 — intervention group
Group type: EXPERIMENTAL
Intervention: Quiet conditions using cellular phone with earpiece (QCPE)
Number of subjects: 20
Study 19497708 — intervention group
Group type: EXPERIMENTAL
Intervention: Noisy conditions using cellular phone (NCP)
Number of subjects: 20
Study 19497708 — intervention group
Group type: EXPERIMENTAL
Intervention: Noisy conditions using cellular phone with earpiece (NCPE)
Number of subjects: 20
Study 19497708 — intervention group
Group type: COMPARATOR
Intervention: All quiet conditions
Number of subjects: 20
Study 19497708 — intervention group
Group type: COMPARATOR
Intervention: Noisy conditions
Number of subjects: 20
Study 18605892 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride varnish application (Fluoridin, Voco) at baseline, 3 months, and 6 months
Number of subjects: 92
Study 18605892 — intervention group
Group type: COMPARATOR
Intervention: Control group (no professional fluoride application)
Number of subjects: 92
Study 15784942 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine-modified glass ionomer cement (CHXGIC)
Number of subjects: 120
Study 15784942 — intervention group
Group type: COMPARATOR
Intervention: Conventional glass ionomer cement (GIC)
Number of subjects: 120
Study 11124748 — intervention group
Group type: EXPERIMENTAL
Intervention: Behenate oil
Number of subjects: 7
Study 11124748 — intervention group
Group type: COMPARATOR
Intervention: Palm oil
Number of subjects: 7
Study 11124748 — intervention group
Group type: COMPARATOR
Intervention: High-oleic acid sunflower oil
Number of subjects: 7
Study 9664583 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation (SCS) using Itrel II System pulse-generator
Number of subjects: 27
Study 8145004 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemofer (2 tablets = 18 mg iron/day)
Number of subjects: 0
Study 8145004 — intervention group
Group type: COMPARATOR
Intervention: Erco-Fer (1 tablet = 60 mg iron/day)
Number of subjects: 0
Study 3071435 — intervention group
Group type: EXPERIMENTAL
Intervention: MaxEPA fish lipid concentrate
Number of subjects: 86
Study 3071435 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 86
Study 1948094 — intervention group
Group type: EXPERIMENTAL
Intervention: Defibrotide 400 mg b.i.d. for 6 months
Number of subjects: 193
Study 1948094 — intervention group
Group type: EXPERIMENTAL
Intervention: Defibrotide 800 mg o.d. for 6 months
Number of subjects: 193
Study 1948094 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 193
Study 1948094 — intervention group
Group type: EXPERIMENTAL
Intervention: Defibrotide 800 mg
Number of subjects: 193
Study 29653 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimepranol (10-14 mg/twice daily)
Number of subjects: 18
Study 29653 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone (50 mg every second day)
Number of subjects: 18
Study 29653 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of trimepranol and chlorthalidone
Number of subjects: 18
Study 29653 — intervention group
Group type: COMPARATOR
Intervention: Chlorthalidone
Number of subjects: 18
Study 29653 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimepranol
Number of subjects: 18
Study 31321636 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (n=108) received a 10-min video clip and brief counseling in addition to an education booklet.
Number of subjects: 244
Study 31321636 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=136) received only an education booklet.
Number of subjects: 244
Study 28193197 — intervention group
Group type: EXPERIMENTAL
Intervention: Psycho-educational intervention (PEI)
Number of subjects: 17
Study 26335089 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial incentives of £15 (US $23) for each long-acting injectable antipsychotic (LAI) received.
Number of subjects: 141
Study 26335089 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (control group).
Number of subjects: 141
Study 26335089 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher total amount of incentives offered.
Number of subjects: 141
Study 22446301 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin (OT)
Number of subjects: 62
Study 22446301 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 20403652 — intervention group
Group type: EXPERIMENTAL
Intervention: Le Fort I osteotomy with down‐grafting and interpositioning of bone (10 patients)
Number of subjects: 27
Study 20403652 — intervention group
Group type: COMPARATOR
Intervention: Raising the sinus floor with onlay bone grafting (17 patients)
Number of subjects: 27
Study 19796583 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary open reduction and internal fixation (PORIF)
Number of subjects: 40
Study 19796583 — intervention group
Group type: COMPARATOR
Intervention: Primary arthrodesis (PA)
Number of subjects: 40
Study 19796583 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (PORIF and PA)
Number of subjects: 40
Study 17822565 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (group I, n = 17)
Number of subjects: 33
Study 17822565 — intervention group
Group type: COMPARATOR
Intervention: Control group (group C, n = 16)
Number of subjects: 33
Study 15514527 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin for duration of tube thoracostomy placement (Group A)
Number of subjects: 224
Study 15514527 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin for 24 hours (Group B)
Number of subjects: 224
Study 15514527 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Group C)
Number of subjects: 224
Study 11133628 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% ropivacaine
Number of subjects: 50
Study 11133628 — intervention group
Group type: COMPARATOR
Intervention: 0.5% bupivacaine
Number of subjects: 50
Study 9562282 — intervention group
Group type: EXPERIMENTAL
Intervention: r‐HuEPO (Eprex)
Number of subjects: 24
Study 9562282 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 7880938 — intervention group
Group type: EXPERIMENTAL
Intervention: Arginine (ARG) 30 g infused over 30 min starting at 0 min
Number of subjects: 11
Study 7880938 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridostigmine (PD) 120 mg orally, 60 min before GHRH administration
Number of subjects: 11
Study 7880938 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH administration
Number of subjects: 11
Study 3067566 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 0
Study 3067566 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen
Number of subjects: 0
Study 3067566 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31630113 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical decision support (CDS) tools implementation
Number of subjects: 60
Study 27935166 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D regimen (ombitasvir, paritaprevir/ritonavir, dasabuvir) with or without ribavirin
Number of subjects: 2027
Study 25957039 — intervention group
Group type: EXPERIMENTAL
Intervention: 2C3L
Number of subjects: 146
Study 25957039 — intervention group
Group type: COMPARATOR
Intervention: stepwise
Number of subjects: 146
Study 23792241 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma N-terminal pro-B-type natriuretic peptide (NT-proBNP)
Number of subjects: 313
Study 21924552 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram 10 mg daily
Number of subjects: 147
Study 21924552 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 147
Study 18270032 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-D segmentation algorithm for lung nodules in CT images
Number of subjects: 107
Study 16943402 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurostimulation of the subthalamic nucleus
Number of subjects: 156
Study 16943402 — intervention group
Group type: COMPARATOR
Intervention: Medication alone (Control)
Number of subjects: 156
Study 14659065 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency endoscopy (group A)
Number of subjects: 91
Study 11214707 — intervention group
Group type: EXPERIMENTAL
Intervention: DDD pacing or oral theophylline
Number of subjects: 0
Study 11214707 — intervention group
Group type: COMPARATOR
Intervention: Control (not treated)
Number of subjects: 0
Study 9598259 — intervention group
Group type: EXPERIMENTAL
Intervention: Ringer's solution (25 ml.kg-1)
Number of subjects: 19
Study 9598259 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextran 3% (10 ml.kg-1)
Number of subjects: 19
Study 7888692 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitoring of blood glucose (SMBG) and dietary carbohydrate (CHO) counting
Number of subjects: 23
Study 7888692 — intervention group
Group type: COMPARATOR
Intervention: Behavioral program without SMBG and CHO counting
Number of subjects: 23
Study 3170960 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulfate (0.27 mmol/kg body weight)
Number of subjects: 28
Study 3170960 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 31570296 — intervention group
Group type: EXPERIMENTAL
Intervention: Dichlorphenamide (50 mg or 100 mg daily for adolescents)
Number of subjects: 73
Study 31570296 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 31570296 — intervention group
Group type: EXPERIMENTAL
Intervention: Dichlorphenamide (105.7 mg mean daily for adults)
Number of subjects: 73
Study 31570296 — intervention group
Group type: EXPERIMENTAL
Intervention: Dichlorphenamide
Number of subjects: 73
Study 28010994 — intervention group
Group type: EXPERIMENTAL
Intervention: One-to-one pelvic floor muscle training (five physiotherapy appointments over 16 weeks, annual review) plus Pilates-based pelvic floor muscle training classes and a DVD for home use
Number of subjects: 414
Study 28010994 — intervention group
Group type: COMPARATOR
Intervention: Prolapse lifestyle advice leaflet
Number of subjects: 414
Study 25494864 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin sensitivity allele score (GS‐InSens)
Number of subjects: 96
Study 25494864 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin secretion allele score (GS‐InSec)
Number of subjects: 96
Study 23243248 — intervention group
Group type: EXPERIMENTAL
Intervention: Myo-inositol at 0.1%
Number of subjects: 60
Study 23243248 — intervention group
Group type: EXPERIMENTAL
Intervention: Phytase B at 1,300 acid phosphatase units/kg
Number of subjects: 60
Study 23243248 — intervention group
Group type: EXPERIMENTAL
Intervention: Phytase B enriched in 6-phytase A at 300 phytase units/kg
Number of subjects: 60
Study 23243248 — intervention group
Group type: COMPARATOR
Intervention: Negative control diet (0.304 g of monocalcium phosphate per kg)
Number of subjects: 60
Study 23243248 — intervention group
Group type: COMPARATOR
Intervention: Internal control diet (adjusted NPP content)
Number of subjects: 60
Study 21884956 — intervention group
Group type: EXPERIMENTAL
Intervention: Ingesting all prescribed hypertension medications upon awakening
Number of subjects: 3344
Study 21884956 — intervention group
Group type: COMPARATOR
Intervention: Ingesting ≥1 of prescribed hypertension medications at bedtime
Number of subjects: 3344
Study 19844206 — intervention group
Group type: EXPERIMENTAL
Intervention: SNPs in ABCB1, SLC6A2, SLC6A3, SLC6A4, CREB1 and NTRK2
Number of subjects: 536
Study 19844206 — intervention group
Group type: EXPERIMENTAL
Intervention: SNPs in ABCB1, SLC6A2 and NTRK2
Number of subjects: 536
Study 19844206 — intervention group
Group type: EXPERIMENTAL
Intervention: NTRK2-coding SNPs (rs2289657 and rs56142442) and haplotype CAG at rs2289658, rs2289657 and rs2289656
Number of subjects: 536
Study 19844206 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 536
Study 16412216 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smoking
Number of subjects: 6961
Study 16412216 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity
Number of subjects: 6961
Study 16412216 — intervention group
Group type: COMPARATOR
Intervention: Adherence to lifestyle recommendations
Number of subjects: 6961
Study 16412216 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette consumption
Number of subjects: 6961
Study 15311218 — intervention group
Group type: EXPERIMENTAL
Intervention: Chitosan (3 g/day)
Number of subjects: 250
Study 15311218 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 250
Study 11517198 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal CPAP delivered through binasal (Hudson) prongs
Number of subjects: 87
Study 11517198 — intervention group
Group type: COMPARATOR
Intervention: Nasal CPAP delivered through a single nasal prong
Number of subjects: 87
Study 9369265 — intervention group
Group type: EXPERIMENTAL
Intervention: SR 49059 (30 mg)
Number of subjects: 12